Latest news with #MichaelCherny
Yahoo
3 days ago
- Business
- Yahoo
Leerink Partners Maintains a Hold on Premier (PINC), Sets a $24 PT
Premier, Inc. (NASDAQ:PINC) is one of the best small cap low volatility stocks to invest in. In a report released on June 30, Michael Cherny from Leerink Partners maintained a Hold rating on Premier, Inc. (NASDAQ:PINC) with a price target of $24.00. A healthcare worker at a desk, monitoring the performance of a Group Purchasing Program. The analyst supported the optimistic rating with several factors, including Premier, Inc.'s (NASDAQ:PINC) recent acquisition of IllumiCare. Cherny stated that the acquisition strategically aligns with Premier, Inc.'s (NASDAQ:PINC) goal of enhancing clinical decision support capabilities and operational efficiency. The analyst added that while the acquisition adds strategic value, he does expect it to add considerably to the company's financials in the near term. Other factors expected to have a significantly higher impact on Premier, Inc.'s (NASDAQ:PINC) performance, according to the analyst, include the ongoing renegotiations of the Group Purchasing Organization (GPO) net admin fee share and larger capital deployment. Premier, Inc. (NASDAQ:PINC) provides healthcare improvement solutions. The company's operations are divided into the Supply Chain Services and Performance Services segments. While we acknowledge the potential of PINC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-07-2025
- Business
- Yahoo
IQVIA beats quarterly estimates on resilient demand for healthcare analytics
(Reuters) -Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading. IQVIA's technology and analytics unit, which serves pharmaceutical and consumer health companies, benefited from higher drug approvals by the U.S. Food and Drug Administration. Still, the company narrowed its annual earnings forecast as drugmakers and biotech companies have been cancelling orders given to contract research firms, in response to the U.S. government's drug price negotiation program, proposed federal research budget cuts and potential tariffs. The Trump administration has been considering separate tariffs for the pharmaceutical industry, which could be as high as 200%. But analysts said that, overall, the quarterly results had "more pluses than minuses." "All-in, this print could have been worse and should clear a fairly low bar heading into the quarter," Leerink Partners analyst Michael Cherny said in a note. Quarterly sales at the technology and analytics unit was $1.63 billion, compared with estimates of $1.60 billion, according to data compiled by LSEG. IQVIA's total quarterly revenue rose 5.3% to $4.02 billion, beating analysts' average estimate of $3.96 billion. On an adjusted basis, it reported profit of $2.81 per share for the quarter ending June 30, above expectations of $2.77 per share. IQVIA now expects annual adjusted profit per share between $11.75 and $12.05, compared with $11.70 to $12.10 earlier. The Durham, North Carolina-based company also narrowed its annual revenue expectations to between $16.1 billion and $16.3 billion, from $16 billion to $16.4 billion earlier. The new forecast assumes a roughly $100 million COVID-related impact. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
22-07-2025
- Business
- Reuters
IQVIA beats quarterly estimates on resilient demand for healthcare analytics
July 22 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading. IQVIA's technology and analytics unit, which serves pharmaceutical and consumer health companies, benefited from higher drug approvals by the U.S. Food and Drug Administration. Still, the company narrowed its annual earnings forecast as drugmakers and biotech companies have been cancelling orders given to contract research firms, in response to the U.S. government's drug price negotiation program, proposed federal research budget cuts and potential tariffs. The Trump administration has been considering separate tariffs for the pharmaceutical industry, which could be as high as 200%. But analysts said that, overall, the quarterly results had "more pluses than minuses." "All-in, this print could have been worse and should clear a fairly low bar heading into the quarter," Leerink Partners analyst Michael Cherny said in a note. Quarterly sales at the technology and analytics unit was $1.63 billion, compared with estimates of $1.60 billion, according to data compiled by LSEG. IQVIA's total quarterly revenue rose 5.3% to $4.02 billion, beating analysts' average estimate of $3.96 billion. On an adjusted basis, it reported profit of $2.81 per share for the quarter ending June 30, above expectations of $2.77 per share. IQVIA now expects annual adjusted profit per share between $11.75 and $12.05, compared with $11.70 to $12.10 earlier. The Durham, North Carolina-based company also narrowed its annual revenue expectations to between $16.1 billion and $16.3 billion, from $16 billion to $16.4 billion earlier. The new forecast assumes a roughly $100 million COVID-related impact.
Business Insider
15-07-2025
- Business
- Business Insider
Is Hims & Hers (HIMS) Stock a Buy After the Recent Pullback? Here's What Analysts Say
Hims & Hers Health (HIMS) stock has declined about 17% over the past month, mainly impacted by its fallout with Novo Nordisk (NVO). The Danish healthcare giant terminated its distribution agreement with Hims & Hers, accusing the telehealth company of illegally selling compounded versions of the weight loss drug Wegovy. Despite the recent selloff, HIMS stock is still up 98% year-to-date. Most Wall Street analysts don't see the correction in Hims & Hers stock as a buying opportunity and are currently cautious due to the ongoing challenges. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Analysts Are Cautious on Hims & Hers Stock Despite the termination of the partnership with Novo Nordisk, Hims & Hers bulls remain confident about the health and wellness platform's growth potential and opportunities in areas beyond GLP-1 drugs. Meanwhile, many analysts are cautious about HIMS stock due to legal risks and valuation concerns. Recently, Hims & Hers Health announced its planned entry into the Canadian market to offer affordable weight loss care. Reacting to the news, Leerink Partners analyst Michael Cherny reiterated a Hold rating on HIMS stock with a price target of $42. The 4-star analyst thinks that HIMS' entry into the Canadian market represents a logical and anticipated next step in its international expansion strategy, especially following the recent ZAVA acquisition. Cherny added that HIMS' move is clearly timed with the expected launch of generic semaglutide (active ingredient in Wegovy) in Canada, allowing HIMS to offer its personalized take/discounted pricing on a generic drug versus the 'ongoing push and pull of its compounded U.S. franchise.' Cherny contended that while the news doesn't come as a surprise, it reinforces HIMS' ability to leverage generically available products in new markets and diversify its revenue base. He views HIMS' expansion into Canada as a potential incremental revenue driver into 2026, 'though execution and uptake will be key to watch.' However, even with the foray into the Canadian market marking a potential contributor, Cherny remains neutral on HIMS stock as the uncertainty of the U.S. weight management franchise continues to create 'non-fundamental earnings volatility.' Meanwhile, analysts from Morgan Stanley and Truist are cautious on Hims & Hers stock due to legal risks. Recently, Truist analyst Jailendra Singh reaffirmed a Hold rating on HIMS stock with a price target of $45. Singh thinks that HIMS faces greater litigation risk after the termination of its short-lived partnership with Novo Nordisk. He noted Novo Nordisk's concerns around HIMS' 'illegal' mass compounding and 'deceptive' marketing practices. He added that while HIMS would argue that its compounding business is not violating any intellectual property (IP), Novo Nordisk could make a legal argument around other practices. A litigation, if there is one, could drag on for 18-24 months and could remain an overhang on HIMS stock, concluded Singh. Is HIMS Stock a Good Buy? Overall, Wall Street is sidelined on HIMS stock based on seven Holds, one Buy, and two Sell recommendations. The average HIMS stock price target of $41 indicates a downside risk of 14.4% from current levels.
Business Insider
12-07-2025
- Business
- Business Insider
Icon (ICLR) Gets a Buy from Leerink Partners
Leerink Partners analyst Michael Cherny reiterated a Buy rating on Icon on July 9. The company's shares closed yesterday at $150.52. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Cherny is a 4-star analyst with an average return of 4.7% and a 54.30% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Cardinal Health, and CVS Health. In addition to Leerink Partners, Icon also received a Buy from Truist Financial's Jailendra Singh in a report issued on July 9. However, on June 25, Barclays maintained a Hold rating on Icon (NASDAQ: ICLR). ICLR market cap is currently $12.28B and has a P/E ratio of 16.38. Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.
